ELSIhub
ELSIhub is an online hub supporting work in ELSI of genetics & genomics.
LinkedIn
LinkedIn
Instagram
Instagram
Bluesky
Bluesky
Threads
Threads
X
X
Email
Email
NEW on ELSIhub
ELSI in Review • March 2026 | ELSIhub
ELSI in Review • March 2026 | ELSIhub
ELSI in Review is a listing of recently published reviews of the literature on key ELSI topics curated by CERA staff. Our March 2026 set explores parent perspectives on genomic sequencing in newborn screening, returning value to communities from the All of Us Research Program, and more. If you would like your ELSI-relevant review featured in this communication, please contact us at info@elsihub.org.
Call for Papers - The ELSI of Genetic Selection
Call for Papers - The ELSI of Genetic Selection
The Center for ELSI Resources and Analysis (CERA) is sponsoring a special report of the Hastings Center Report that considers the ethical, legal, and social implications (ELSI) of reproductive technologies, practices, and policies that enable the selection of genetic characteristics. The guest editors of the report are Josephine Johnston, Deanne Dunbar Dolan, Mildred K. Cho, and Sandra Soo-Jin Lee.
The 7th ELSI Congress
The 7th ELSI Congress
7th ELSI Congress | 2026
6th ELSI Congress Special Issue of AJOB
6th ELSI Congress Special Issue of AJOB
We are pleased to announce the publication of a special issue of the American Journal of Bioethics.
Events
March ELSI Friday Forum | Constrained Choice: Autonomy and Reproductive Genomics in Pregnancy Outcomes
March ELSI Friday Forum | Constrained Choice: Autonomy and Reproductive Genomics in Pregnancy Outcomes
Recording | February 2026 EFF: Just CRISPR
Recording | February 2026 EFF: Just CRISPR
In 2025, KJ Muldoon was the first patient to be treated for a life-threatening genetic disorder with gene editing therapy. KJ received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency (CPS1) as a neonate, and received treatment when he was 7 months old, under Expanded Access approval from the FDA. Because rare diseases such as CPS1 cannot be evaluated in traditional clinical trials, regulators are considering new pathways to approval for broader populations.
Resources
The Leading Resource for ELSI Research | ELSIhub
The Leading Resource for ELSI Research | ELSIhub
Collections | ELSIhub
Collections | ELSIhub
View on mobile
Explore other Linktrees
Hailey Elizabeth
@haileyelizabethh
gigglysquad
@gigglysquad
Ken Eurich
@keneurich
OrelSanTour2026
@OrelSanTour2026
Kaitlyn Johnson
@missynjohnson
Aimee Kelly
@byaimeekelly
fiajames
@fiajames
Tara Davis Hall
@taradaviswoodhall
Michelle Ahn
@ohtheplacesyoullgrow
Jeremiah Brown
@FindJeremiah
previous
next
Discover more
See all
@alicelingerieoficiall
@AmnestyInternationalMSJC
@barbaraobreque
@Jakejoey
@goldendaggerpiercings
@kaentific
@chellyban
@meinmakler.bochum
@jane_creaciones
@floret.studio
@jakeventure
@sriraga_cococoir
@renatacasagrande
@a7medoos
@nevadaoutdoorschool
@Thatsocraven
@easytravelingwithe
@valdir.ramos.francisco
@callmeerahul.ai
@piskeimoveis
@honeygloe
@beardos
@The.wholehearted.np
@thehomeednest
@bringingupbergs
@outletwholesaledistributors
@theodor.nicu
@moonstrukk
@brassbandnw
@perimenomayhem
@ipanglazuardi
@atlas.assessoria
@newlengthsbeautyco
@silvio.evanni
@hopewestnashville
@jeknibosss
@semolinapilchard
@lynettelockenphotography
@kura_campers
@novacastelo.pizzaria
@positivewellbeinghk
@japanesesake_hachimitsu
@ucsbzerowaste
@lilebendy
@adamstaples